FDA Moves, RNA Biotech Deals
Kilder
- STAT: STAT+: FDA approves AstraZeneca breast cancer drug
- Raps: Recon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, myotonic dystrophy - RAPS
- Endpoints: BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T
- Fierce Biotech: BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer - Fierce Biotech
- BioSpace: BrainChild Bio targets deadly pediatric brain cancer with $116M series A - BioSpace
- GEN: RNAV8 Bio Joins ARPA-H Team to Pioneer Programmable RNA Medicines
- GEN: ProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell Line - Genetic Engineering and Biotechnology News
- GEN: Measuring Cell Line Development Quality Within Days of Single-Cell Cloning, Not Months Later - Genetic Engineering and Biotechnology News
- BioPharma Dive: Moonwalk reloads with $70M and new RNAi prospects for obesity
- STAT: STAT+: Inhibrx claims first win for long-sought immunotherapy target
- STAT: FDA names acting heads of drug and vaccine centers to permanent roles - STAT
- Endpoints: Diabetes cell therapy biotechs Sernova and Seraxis to merge
- Bizjournals: Germantown's Seraxis merging with Ontario biotech to pursue Type 1 diabetes cure - The Business Journals
- Streetwisereports: Biotechs Combine to Target Type 1 Diabetes Treatment - Streetwise Reports
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.